Annual report pursuant to Section 13 and 15(d)

Revenue Recognition

v3.20.1
Revenue Recognition
12 Months Ended
Dec. 31, 2019
Revenue Recognition [Abstract]  
Revenue Recognition

3.       Revenue Recognition

 

Revenue by Service Line

 

    Years Ended December 31,  
    2019     2018  
Products:            
Disposable products:                
Functional neurosurgery   $ 6,884,085     $ 5,351,557  
Biologics and drug delivery     1,458,850       913,424  
Therapy     96,925        
       Capital equipment     1,036,505       420,039  
Total product revenue     9,476,365       6,685,020  
Services:                
Biologics and drug delivery     889,702       175,223  
Therapy     225,000       100,000  
Capital equipment and other     625,870       393,023  
Total service revenue     1,740,572       668,246  
Total revenue   $ 11,216,937     $ 7,353,266  

 

Contract Balances

 

Contract assets – Substantially all the Company’s contracts with customers are based on customer-issued purchase orders for distinct products or services. Customers are billed upon delivery of such products or services, and the related contract assets comprise the accounts receivable balances included in the accompanying consolidated balance sheets.

 

Contract liabilities – The Company generally bills and collects capital equipment-related service fees at the inception of the service agreements, which have terms ranging from one to three years. The unearned portion of such service fees are classified as deferred revenue.

 

During the year ended December 31, 2019, the Company recognized capital equipment-related service revenue of approximately $228,000 which was previously included in deferred revenue in the accompanying consolidated balance sheet at December 31, 2018.

 

In September 2019, the Company entered into a Development Services Agreement with a customer under which the Company was entitled to bill the customer for an upfront payment of $127,600, of which $102,000 is included in deferred revenue in the accompanying December 31, 2019 consolidated balance sheet. In September 2019, the Company entered into a Letter of Intent (the “LOI”) with a customer who is a stockholder and whose Chief Operating Officer is a member of the Company’s Board of Directors. The purpose of the LOI was to permit the commencement of a product development project in anticipation of negotiating a detailed Statement of Work (the “SOW”) which was entered into in November 2019. Under the terms of the LOI, the Company was entitled to bill the customer for an upfront, nonrefundable payment of $500,000, and under the terms of the SOW, the Company was entitled to bill the customer on a quarterly basis, commencing in the fourth quarter of 2019, for service fees of $500,000. The Company recognizes as revenue each of the upfront payments described in this paragraph in proportional relationship to the transaction prices of the performance obligations contained in the related agreements, and recognizes as revenue the quarterly service fees described in this paragraph as stand-by services which commenced during the fourth quarter of 2019. Based on the foregoing, $625,000 of the aggregate amount of all the payments described in this paragraph were included in deferred revenue in the accompanying consolidated balance sheet at December 31, 2019.

 

During the year ended December 31, 2019, the Company offered an upgraded version of its software at no additional charge to customers purchasing a three-year systems service agreement. The transaction prices of the software and the service agreement were determined through an allocation of the service agreement price based on the standalone prices of the software and the service agreements. The transaction price of the software was recognized as revenue upon its installation and comprised approximately $172,000 of unbilled amounts included in accounts receivable in the accompanying December 31, 2019 consolidated balance sheet.

 

Remaining Performance Obligations

 

The Company’s contracts with customers, other than capital equipment-related service agreements discussed below, are predominantly of terms less than one year. Accordingly, the transaction price of remaining performance obligations related to such contracts at December 31, 2019 are not significant.

 

Revenue with respect to remaining performance obligations related to capital equipment-related service agreements with original terms in excess of one year and the upfront payments discussed under the heading “Contract Balances” above amounted to approximately $1.1 million at December 31, 2019. The Company expects to recognize this revenue within the next three years.